Related Experiment Video

Updated: Dec 28, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.2K

Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design

Rafael Romaguera1, Pablo Salinas2, Salvatore Brugaletta3

  • 1Hospital de Bellvitge - IDIBELL, University of Barcelona, Barcelona, Spain.

American Heart Journal
|February 23, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique
11:07

Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique

Published on: October 1, 2017

11.5K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.7K

Related Experiment Videos

Last Updated: Dec 28, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.2K
Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique
11:07

Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique

Published on: October 1, 2017

11.5K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.7K

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

301
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
301
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

274
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
274

Articles linked to this work by shared authors, journal, and citation graph.

A hybrid phenomenological finite element model of transcatheter aortic valve leaflet behaviour under non-circular annular deployment: in vitro validation and biomechanical insights.

Biomechanics and modeling in mechanobiology·2026

Hypoattenuated Leaflet Thickening After TAVR: Incidence, Predictors, and the Role of Platelet Reactivity: A Prospective Multicenter Observational Study.

Journal of clinical medicine·2026

Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.

GeroScience·2026

Impact of Supranormal LVEF After TAVI: Behavior, Mortality, and Cardiac Structure.

Journal of clinical medicine·2026

The Long-Term Outcomes of Corticosteroid Use in COVID-19 Patients with Cardiovascular Disease: A Propensity-Matched Analysis from the Multi-Center International Prospective Registry (HOPE-2).

Biomedicines·2025

Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation.

American heart journal·2025

Cardiorespiratory Fitness in Children with Surgically Corrected Congenital Heart Disease: Exercise Testing Profiles and Biventricular Function.

American heart journal·2026

High-Sensitivity HEART Pathway One-and-Done Troponin Strategy is Safe and Effective.

American heart journal·2026

Health Status Relationship to Ischemia and Coronary Artery Disease Severity in the ISCHEMIA Trial.

American heart journal·2026

Guideline-Directed Medical Therapy and Clinical Outcomes in Adults with Fontan Palliation and Systemic Ventricular Systolic Dysfunction.

American heart journal·2026

Comparative effectiveness of influenza vaccination dosing strategies for cardiovascular protection: a systematic review and network meta-analysis of randomised controlled trials.

American heart journal·2026

Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: an integrated analysis of phase 3 clinical trials.

American heart journal·2026

Impact of hydrolyzed gelatin and hydroxypropyl-β-cyclodextrin as polymeric excipients on physical stability and injectability of high-concentration protein suspensions.

International journal of pharmaceutics·2026

A combined approach for full API particle size distribution characterization in nasal spray suspensions based on their dissolution behavior.

Journal of pharmaceutical sciences·2026

Key strategic considerations for pooling multiple drug substance batches in biopharmaceutical drug product manufacturing.

Journal of pharmaceutical sciences·2026

Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters.

Clinical pharmacokinetics·2026

PNI, CONUT, and GNRI for predicting treatment failure in peritoneal dialysis-associated peritonitis: a two-center retrospective study.

Frontiers in nutrition·2026

Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem.

Drug safety·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us